Phase II Trial of Nintedanib in Patients With Advanced Esophagogastric Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 22 May 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 20 May 2019 Planned End Date changed from 1 Sep 2019 to 1 Sep 2020.
- 20 May 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 05 Apr 2019 Results published in the Clinical Cancer Research